<figure><img alt="Woman With Binoculars" data-src="https://vertassets.blob.core.windows.net/image/e5a0ad6e/e5a0ad6e-66cf-48a6-bc87-4273c6cc71ad/375_250-istock_1186786870.jpg" src="https://vertassets.blob.core.windows.net/image/e5a0ad6e/e5a0ad6e-66cf-48a6-bc87-4273c6cc71ad/375_250-istock_1186786870.jpg"></img><figcaption>Woman With Binoculars</figcaption></figure>
<p>One can easily argue that we have seen more innovation in the pharmaceutical industry in the last decade than in the past 50 years. The tools we use today to characterize and construct drug therapies, from next-generation gene sequencing technologies to CRISPR/Cas9, give us unprecedented capabilities to identify and treat new disease states. However, these technologies would not have been so influential in the absence of a regulatory framework within which to apply them. The FDA regulates the largest pharmaceutical market in the world and, as such, sets the bar suitably high for drug sponsors to demonstrate safety and efficacy.</p>
<p>In 2020, the FDA recognized that a new approach was required to keep pace with the rapid evolution of science and technology driving drug development, and it <a href="https://www.fda.gov/media/145001/download">released the report Advancing Regulatory Science at FDA: Focus Areas of Regulatory Science (FARS)</a> early in 2021 to identify and communicate areas requiring continued targeted investment. The acronym is apt, as the report is remarkably far reaching. Across the myriad of focus areas of the report&rsquo;s major FDA Strategic Initiatives (Public Health Preparedness and Response, Increasing Choice and Competition through Innovation, Unleashing the Power of Data, and Empowering Patients and Consumers), five key elements deserve our attention.</p>
<h2>1. Patient-Centricity And Real-World Evidence</h2>
<p>The COVID pandemic provided the push needed for telemedicine to get a foothold in modern healthcare standard of care. This crisis has not only proven the viability of telemedicine but has also reinforced the notion of patients managing their own health through the use of digital health solutions and patient portals where they can keep tabs on their own care and treatment. Improving the lives of patients requires a deep understanding of their medical conditions, their experiences, needs, and priorities. Patient-centricity <a href="https://innovations.bmj.com/content/3/2/76">can be described as</a> &ldquo;putting the patient first in an open and sustained engagement of the patient to respectfully and compassionately achieve the best experience and outcome for that person and their family.&rdquo; With a renewed emphasis on education co-creation, information access, and transparency, the FDA has embraced the era of patient-centricity to regularly engage consumers in patient listening sessions and patient-focused drug development public meetings.</p>
<p>Real-world data (RWD) are data relating to a patient&rsquo;s health status and/or the delivery of healthcare routinely collected from a variety of sources. Examples of RWD include data derived from electronic health records (EHRs), administrative claims, registries, patient-generated data, and data gathered from mobile devices and other digital health technologies. Real-world evidence (RWE) refers to clinical evidence about the usage, potential benefits, or risks of an FDA-regulated product derived from analysis of RWD. The FDA is committed to exploring the use of RWE in regulatory decision-making, including providing fit-for-purpose and clinically meaningful information about the safety and effectiveness of medical products. Support for many RWE initiatives includes funding a demonstration project known as RCT-DUPLICATE (Randomized, Controlled Trials Duplicated Using Prospective Longitudinal Insurance Claims: Applying Techniques of Epidemiology). The RCT-DUPLICATE initiative attempts to duplicate the results of recently completed clinical trials relevant to regulatory decision-making using RWE, based on health insurance claims data.</p>
<p>A key concept of patient-centricity was included in the <a href="https://www.fda.gov/regulatory-information/selected-amendments-fdc-act/21st-century-cures-act">21<sup>st</sup> Century Cures Act</a>, which introduced clinical outcome assessments (COAs). COAs capture how patients feel and function by measuring a patient&rsquo;s symptoms, mental state, effects of the disease or condition. Patient interviews and surveys are used to determine how messaging, labeling statements, and therapeutic claims affect patients&rsquo; and consumers&rsquo; understanding of their disease state and treatment as well as the patient&rsquo;s decision making.</p>
<h2>2. Biomarker Research</h2>
<p>One challenge drug developers have encountered is to define the mode and mechanism of action, especially in the rapidly expanding area of cell and gene therapy. In many cases, the ability to identify biomarkers that support the putative mechanism of action is the <em>only</em> path to establishing a defensible potency matrix and quality assurance argument.</p>
<p>Biomarkers can also play a critical role in bridging non-clinical results to clinical research. That is why the FDA and the National Institutes of Health (NIH) are working together to advance biomarker research by promoting consistent biomarker terms and concepts. A three-step qualification process for new biomarkers requires a letter of intent for the qualification of a development tool, a qualification plan, and a qualification package comprising the approach for defining the biomarker.</p>
<h2>3. AI And Computer Modeling</h2>
<p>The FDA has applied machine learning in a practical initiative to leverage artificial intelligence that looks for data anomalies in the agency&rsquo;s monitoring programs and to predict submission timing as a way to improve the efficiency of reviewing regulatory submissions.</p>
<p>The agency is encouraging the application of computer modeling as part of the product development life cycle. Model-informed product development (MIPD) aims to integrate information from diverse data sources to help relieve uncertainty and lower failure rates and to develop information that cannot, or would not, be generated experimentally. MIPD encompasses model-informed drug development (MIDD), an approach that involves developing and applying exposure-based biological and statistical models derived from preclinical and clinical data sources to inform drug development or regulatory decision-making.</p>
<p>Computer modeling can inform researchers on the efficiency of clinical trial designs, providing evidence for efficacy, product performance, and safety predictions. The willingness of the agency to stray from a classical clinical trial design is a big acknowledgement that alternative approaches may be equally effective in demonstrating safety and efficacy.</p>
<h2>4. Advanced Manufacturing</h2>
<p>One by-product of the COVID-19 pandemic was that it exposed many nations&rsquo; dependence on external suppliers for chemical precursors, active pharmaceutical ingredients (APIs), and critical drug therapies. In response, the FDA has <a href="https://www.outsourcedpharma.com/doc/fda-steps-up-support-for-advanced-manufacturing-technologies-0001">renewed its support for advanced manufacturing technologies</a>. <em>Advanced manufacturing</em> is a collective term for innovatively applied or new medical product manufacturing technologies and processes that can improve quality, enhance efficiency, address shortages of medical products, or speed time-to-market. Advanced manufacturing techniques being applied to FDA-regulated medical products include additive manufacturing (also known as 3D printing), continuous manufacturing, modularization, and &ldquo;smart&rdquo; manufacturing. There are examples across all medical product areas that include continuous manufacturing and modularization. &ldquo;Smart&rdquo; manufacturing concepts use automation, digitization, and artificial intelligence to streamline production methods, collect process control data, and ultimately use algorithms to adaptively control or make decisions about production or release. The FDA&rsquo;s emphasis on advanced manufacturing &mdash; in particular, continuous manufacturing &mdash; is a major driver behind the resurgence of onshoring initiatives within the U.S.</p>
<h2>5. The Power Of Data</h2>
<p>Perhaps the most strategic initiative is the FDA&rsquo;s focus on harnessing the power behind data, and a significant expanding area is digital health. Digital health technologies (DHTs) use computing platforms, digital connectivity, software, and sensors for healthcare and related uses. We see digital platforms moving healthcare from the clinic to patients by improving understanding of patient behavior and physiology outside traditional clinical settings and enabling early therapeutic interventions. In clinical trials, telehealth tools provide important opportunities to gather information directly from patients at home in decentralized clinical trials, or as part of pharmacovigilance, and gather frequent or continuous medical data from patients as they go about their lives. But DHTs can use advanced algorithms susceptible to potential errors, which may lead to malfunction or misinterpretation of health data. Consequently, regulatory science tools and methods&mdash;such as simulations to test algorithm performance&mdash; need to be developed to protect data integrity and improve overall reliability of DHTs.</p>
<h3>Conclusion</h3>
<p>FDA&rsquo;s Focus Areas of Regulatory Science capture an agency that is looking to provide meaningful regulatory insight on new and emerging approaches to drug development and governance. While we have touched on a few of the major initiatives underway within the FDA, the FARS report provides insight as to the agency&rsquo;s current thinking across a large number of strategic initiatives to meet scientific and technological issues for the foreseeable future.</p>
<p><strong>About The Author:</strong></p>
<p>Bikash Chatterjee is CEO of Pharmatech Associates. He has over 30 years&rsquo; experience in the design and development of pharmaceutical, biotech, medical device, and IVD products. His work has guided the successful approval and commercialization of over a dozen new products in the U.S. and Europe. Chatterjee is a member of the USP National Advisory Board and is the past chairman of the Golden Gate Chapter of the American Society of Quality. He is the author of Applying Lean Six Sigma in the Pharmaceutical Industry and is a keynote speaker at international conferences. Chatterjee holds a B.A. in biochemistry and a B.S. in chemical engineering from the University of California at San Diego.</p>

Food and Drug Administration

regulation

drug development

science

Regulatory

SciTech

science and technology studies

One can easily argue that we have seen more innovation in the pharmaceutical industry in the last decade than in the past 50 years. The tools we use today to characterize and construct drug therapies, from next-generation gene sequencing technologies to CRISPR/Cas9, give us unprecedented capabilities to identify and treat new disease states. Howeve

FDA's 2021 Focus Areas Of Regulatory Science: 5 Trends To Watch

Search by
BioLaurus
Company Headquarters
2305 Historic Decatur Road , Suite 100, San Diego, CA, 92106, US
Driving Directions Phone: View Phone
View website
Request more information from BioLaurus
Request more information from BioLaurus
Please select Job Function NoneResearch & DevelopmentQuality Assurance/Control ValidationBusiness DevelopmentContr

Categories from BioLaurus

A client in Ireland acquired an aseptic operations facility with plans to expand into GMP microbiology laboratory services, despite having previously outsourced all microbiology work and lacking in-house expertise. Eurofins Professional Scientific Services (PSS) addressed this challenge by deploying a dedicated team of 13 employees working in three

Set Up And Qualify GMP Laboratories

In this interview, Steven Facer, Senior Vice President of Global Sales and Marketing at Adare Pharma Solutions, outlines the essential elements of successful CDMO partnerships in today’s fast-paced, complex pharmaceutical environment. With shrinking timelines and rising development challenges, sponsors increasingly rely on CDMOs that offer deep ora

The Secrets Of A Successful CDMO Partnership

Take the time to understand what you have in place and what you need to do to improve. Without a complete and comprehensive understanding of the current processes, it’s incredibly difficult to make sure that you don’t end up in a worse situation than where you started. This is especially true when you’re working with an array of different processes

Operational Resilience:

The European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) have issued recommendations through the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) for securing the supply of anti-D immunoglobulins used to prevent RhD immunization during pregnancy in the European Union. The supply is in trouble becaus

EMA Moves to Secure Supply of Critical Drugs Used During Pregnancy

This week's episode is one from the road, recorded in front of a live audience in Boston's Seaport neighborhood during the BIO conference (special thanks to MasterControl for making it happen). Amber Salzman, Ph.D., CEO of Epicrispr Biotechnologies (aka 'Epic Bio') explains how epigenetic editing is revolutionizing genetic medicine by controlling g

BoB Live At BIO: Amber Salzman, Ph.D., Epicrispr Biotechnologies

Arcus Biosciences announced that quemliclustat, an investigational small-molecule CD73 inhibitor, was granted orphan drug designation by the U.S. Food and Drug Administration to treat pancreatic cancer.
Orphan drug designation is intended to support the development and evaluation of new treatments for rare diseases affecting fewer than 200,000 peop

Arcus' Quemliclustat Receives Orphan Drug Designation

Joachim Kreuzburg, the long-time former CEO of leading biotechnology firm Sartorius, has reemerged at Cube Biotech, where he has joined the board of directors.
The appointment has injected a shot of star power into the German biotech firm, which serves as a supplier much like Kreuzburg’s former company. But unlike his former company, Cube Biotech i

Former Sartorius boss leads class of biotech executive shakeups

By Laura Walls, PhD, Technical Project Leader, and Sharyn Farnsworth, MSc, Director of Upstream Development
The use of Baculovirus expression vector systems (BEVS) in insect cells is a highly efficient and scalable method for producing biologics. This technology is particularly effective in producing high concentrations of multi-protein subunit com

The Perfect Hosts For Vaccine And Virus Expression: Insect Cell Expression Systems

Thursday, July 10, 2025
IASO Biotherapeutics a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative cell therapies and biologics, today announced that its self-developed anti-BCMA CAR-T cell therapy product, Equecabtagene Autoleucel (Fucaso), has been granted Orphan Drug Designation (OD

IASO Bio Receives Orphan Drug Designation from the Ministry of Food and Drug Safety of South Korea for Equecabtagene Autoleucel

Medical Device Recalls
VersaCross RF Wire (VXW). Indicated for creation of an atrial septal defect in the heart. Product...
2
07/10/2025
Boston Scientific Corporation
Bravo CF capsule delivery device, designed to place and attach a pH monitoring capsule to the esopha...
1
07/10/2025
Given Imaging Ltd.
BiPAP A40 Ventilator. Used to provide noninvasi

Medical Device Recalls

Application for Single Medicine Product
A single medicine product is a medicine that consists of one single medicine unit.
Client Reference
The Client Reference field is the Sponsor's or Agent's own internal reference information. This reference information is not visible to TGA when the application is submitted.
Applicant Details
Applicant Name
Th

PM - Application for Single Medicine Product

Complete Response Letters On-Line – Never Thought It Would Happen!
I opened my browser this morning at 6AM PST and the first thing I saw was an FDA notice I never thought I would see. Right there on my computer, the Notice (here) said “FDA Embraces Radical Transparency by Publishing Complete Response Letters”. Yes, that’s right – CRLs are now being

Complete Response Letters On-Line – Never Thought It Would Happen!

US pharma major AbbVie (NYSE: ABBV) and IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation today announced an exclusive licensing agreement for IGI's lead investigational asset, ISB 2001, developed using IGI's proprietary BEAT protein platform, for oncology and autoimmune diseases.
The deal is potentially wo

AbbVie and Ichnos Glenmark ink antibody license deal

Gilead Sciences Inc. has partnered with the Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund) to supply lenacapavir—Gilead’s twice-yearly injectable HIV-1 capsid inhibitor—for the prevention of HIV as pre-exposure prophylaxis (PrEP).
Through the agreement, Gilead will supply enough doses to reach up to two million people over three

Gilead & Global Fund Partner for HIV Prevention

Thursday, July 10, 2025
Sartorius Stedim Biotech has entered into a Memorandum of Understanding (MoU) with Sensible Biotechnologies to support the scale-up and industrialisation of Sensible’s cell-based mRNA design and manufacturing platform.
The collaboration aims to enable the clinical-grade production of cell-based mRNA by 2026. It is expected t

Sartorius Stedim Biotech and Sensible Biotechnologies to Scale Up Cell-Based mRNA Manufacturing Platform

French biotech Osivax has published results from a Phase IIa trial showing that its lead candidate OVX836, a broad-spectrum influenza vaccine, demonstrated a strong safety profile and immune response when administered alongside a conventional flu shot.
The findings, now available in the journal Vaccines, stem from a 180-person study evaluating the

Osivax reports positive mid-stage data for flu vaccine candidate OVX836

Emmanuel Cansino (Senior Director Industry Solutions) will present the webinar Why is Manual Validation Holding you Back? The Evolution of AI-Driven Validation in Regulated Industries on Aug 6, at 8:00 AM EDT. There is a second session at 12:00 PM EDT.
Manual validation, while thorough, often leads to delays, human errors, and compliance headaches.

Why is Manual Validation Holding you Back? The Evolution of AI-Driven Validation in Regulated Industries

Proteros biostructures GmbH, an early-stage drug discovery services provider in Germany, has announced an agreement with Qanatpharma of Switzerland, Zuse Institute Berlin (ZIB), and Ukraine-based Enamine to launch a research collaboration intending to leverage innovations from all four partners—notably, ZIB’s artificial intelligence (AI)-based gene

Generative AI-Driven Collaboration to Research Treatments for Brain Hemorrhage Complications

Aptar CSP Technologies, part of AptarGroup, Inc. and a leader in active material science, has developed a dual-active material science technology engineered to simultaneously control moisture and oxygen. This technology is designed to provide a singular solution to address these degradation drivers for pharmaceutical drugs, including oral solid dos

Aptar Develops Moisture and Oxygen Controlling Technology

I return you to five minutes before Donald Trump officially became president on January 20th, and to a time when the FDA was near perfect.
That’s what one would assume today listening to the many of us up in arms over the agency.
Of course, the reality was quite different. We seem to have erased the memory that segments of our biopharma industry –

The FDA Was Darned Near Perfect, Right?

Getty images. Credit: Tom Werner
Some 75% majority of Americans struggle to take their medications as directed, according to the National Library of Medicine (NLM). This widespread problem—known as medication nonadherence—can make medications ineffective leading to significant worsening of disease, increased medical costs, or death. There are 125,0

New Packaging Breakthrough Reduces Medication Nonadherence

Wednesday, July 09, 2025
Veeda Lifesciences, a global contract research organization (CRO), has announced an investment in Mango Sciences, a Boston-based healthcare AI and data company. Through this investment, Veeda intends to leverage AI capabilities to enhance the speed, efficiency, and quality of Clinical Trials services across its expanded glo

Veeda Lifesciences announces partnership with Mango Sciences to bring AI innovation in clinical trials services

An official website of the European Union
en
Public Health
Home
Publications
Report on the implementation of the EU Global Health Strategy
Background document
Report on the implementation of the EU Global Health Strategy
Page contents
Details
Files
Details
Publication date
Author
Directorate-General for Health and Food Safety
Files
10 JULY 2025
int

Report on the implementation of the EU Global Health Strategy

Search Query: root_codes_comments:"Dopamine receptor antagonist"
Browse Substances
Newest Change
Sort By
Search Within Results
Items per page:
10
1 – 1 of 1
Page:
of 1
METOCLOPRAMIDE
L4YEB44I46
ACHIRAL
Names:
Loading
Relationships:
25
Mol. Weight:
299.8
Formula:
C14H22ClN3O2
Substance Hierarchy
Loading
Items per page:
10
1 – 1 of 1
Page:
of 1

Browse Substances

Advertise in the PDA News uPDAte & Buyer’s Guide

Contact

Advertise

Other industries

With the increased expectation to adopt modern microbial methods, more technology users are being tasked with evaluating and developing implementation strategies for advanced methods.
There is a desire to couple regulatory guidelines with industry expertise to develop standardized tools that make implementation a less daunting task and one that is